New recommendations for using next-generation sequencing in the setting of metastastic cancer have been published by the European Society for Medical Oncology (ESMO).
Experts at the organization used a rigorous methodology to identify advanced cancers with firm evidence supporting the clinical utility of next-generation sequencing (NGS), and other cancers with insufficient data to recommend widespread and routine clinical application of this technology (Ann Oncol 2020 Aug 24. [Epub ahead of